Meta-analyses of real-world evidence (RWE) studies provide valuable insights from unselected patient populations in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that selectively neutralizes IL-17A, has shown long lasting effectiveness and safety in moderate to severe plaque psoriasis (PsO). Since its license approval in 2015, many RWE studies have been published. Here, we reviewed all available literature on RWE studies involving secukinumab in patients with moderate to severe PsO to evaluate its effectiveness, drug survival and safety. Materials and methods https://www.embase.com and https://clinicaltrials.gov databases were searched using pre-specified inclusion criteria from 1/1/2015 to 31/5/2019. Outcomes were measured at 3, 6, and 12 months, and analyzed using a meta-package and R statistical software.